中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

3237 records (took 0.025 seconds)

    Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
    321.
    发明专利
    Compositions and methods relating to universal glycoforms for enhanced antibody efficacy 未知

    公开(公告)号：IL249195D0

    公开(公告)日：2017-01-31

    申请号：IL24919516

    申请日：2016-11-24

    Applicant: ACADEMIA SINICA

    IPC: C07K20060101

    Abstract: The present disclosure relates to an α-fucosidase having α-(1,2), α-(1,3), α-(1,4), and α-(1,6) fucosidase activity. The present disclosure also relates to the compostions comprising the α-fucosidase, and the methods of producing and using the α-fucosidase in cleaving α-(1,2), α-(1,3), α-(1,4), and/or α-(1,6)-linked fucoses in the glycoconjugates.

    Fucosidase from bacteroides and methods using the same
    322.
    发明专利
    Fucosidase from bacteroides and methods using the same 未知

    公开(公告)号：IL249183D0

    公开(公告)日：2017-01-31

    申请号：IL24918316

    申请日：2016-11-24

    Applicant: ACADEMIA SINICA

    IPC: C12N20060101

    Abstract: The present disclosure relates to an α-fucosidase having α-(1,2), α-(1,3), α-(1,4), and α-(1,6) fucosidase activity. The present disclosure also relates to the compostions comprising the α-fucosidase, and the methods of producing and using the α-fucosidase in cleaving α-(1,2), α-(1,3), α-(1,4), and/or α-(1,6)-linked fucoses in the glycoconjugates.

    Fucosidase from bacteroides and methods using the same
    323.
    发明专利
    Fucosidase from bacteroides and methods using the same 未知

    公开(公告)号：AU2015267051A1

    公开(公告)日：2017-01-12

    申请号：AU2015267051

    申请日：2015-05-27

    Applicant: ACADEMIA SINICA

    Inventor： WONG CHI-HUEY ,  TSAI TSUNG-I

    IPC: C12N9/24

    Abstract: The present disclosure relates to an a-fucosidase having a-(1,2), a-(1,3), a-(1,4), and a-(1,6) fucosidase activity. The present disclosure also relates to the compositions comprising the α-fucosidase, and the methods of producing and using the α-fucosidase in cleaving a-(1,2), a-(1,3), a-(1,4), and/or a-(1,6)-linked fucoses in the glycoconjugates. Accordingly, the present invention provides the compositions and methods for the improved enzymatic hydrolysis of fucose in vitro. In particular, the present invention is useful for the efficient cleavage of core fucose in native glycoproteins without denaturation or functional deterioration of glycoproteins. The compositions and methods of the invention can facilitate the Fc glycoengineering of Fc fusion proteins or antibodies, such as therapeutic antibodies.

    Anti-TNF-alpha glycoantibodies and uses thereof
    324.
    发明专利
    Anti-TNF-alpha glycoantibodies and uses thereof 未知

    公开(公告)号：AU2015267044A1

    公开(公告)日：2016-12-15

    申请号：AU2015267044

    申请日：2015-05-27

    Applicant: ACADEMIA SINICA

    Inventor： WONG CHI-HEUY ,  WU CHUNG-YI

    IPC: A61K39/395

    Abstract: The present disclosure relates to a novel class of anti-TNFα monoclonal antibodies or antigen binding fragments comprising a homogeneous population of anti-TNFα IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-TNFα monoclonal antibodies by Fc glycoengineering. The glycoantibodies of the invention may have improved therapeutic values compared to the corresponding monoclonal antibodies that have not been glycoengineered.

    ANTI-VEGFR2 HUMAN ANTIBODY FOR ANTI-ANGIOGENIC AND TARGETED CANCER THERAPY
    325.
    发明专利
    ANTI-VEGFR2 HUMAN ANTIBODY FOR ANTI-ANGIOGENIC AND TARGETED CANCER THERAPY 未知

    公开(公告)号：CA2981883A1

    公开(公告)日：2016-10-20

    申请号：CA2981883

    申请日：2016-04-12

    Applicant: ACADEMIA SINICA

    Inventor： WU HAN-CHUNG ,  LU RUEI-MIN ,  CHIU CHIUNG-YI ,  LIU I-JU ,  CHANG YU-LING

    IPC: C07K16/28

    Abstract: An isolated antibody or an antigen-binding fragment thereof having a specific binding affinity to an epitope located within the domain 1 or domain 3 of human vascular endothelial growth factor receptor 2 (VEGFR2; SEQ ID NO: 74) is disclosed. The epitope within the domain 3 of the VEGFR2 is located between amino acid residues 250 and 270 of SEQ ID NO: 74. Use of the antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting tumor growth, tumor angiogenesis, and/or inducing cancer cell cytotoxicity in a subject in need thereof is also disclosed. Also disclosed is a method of detecting the presence of VEGFR2 in a tumor vascular endothelial cell or a cancer cell in a biological sample.

    Compounds for use in prevention and treatment of neurodegenerative diseases and pain
    328.
    发明专利
    Compounds for use in prevention and treatment of neurodegenerative diseases and pain 未知

    公开(公告)号：IL245103D0

    公开(公告)日：2016-06-30

    申请号：IL24510316

    申请日：2016-04-13

    Applicant: ACADEMIA SINICA

    IPC: C07D20060101

    Abstract: Compounds for use in prevention and treatment of neurodegenerative disease and pain are disclosed. In one embodiment of the invention, the compound is selected from the group consisting of N6-[(3-halothien-2-yl)methyl]adenosine, N6-[(4-halothien-2-yl)methyl]adenosine, and N6-[(5-halothien-2-yl)methyl]adenosine. In another embodiment of the invention, the compound is selected from the group consisting of N6-[(2-bromothien-3-yl)methyl]adenosine, N6-[(4-bromothien-3-yl)methyl]adenosine, N6-[(5-bromothien-3-yl)methyl]adenosine N6-[(2-chlorothien-3-yl)methyl]adenosine, N6-[(4-chlorothien-3-yl)methyl]adenosine, and N6-[(5-chlorothien-3-yl)methyl]adenosine. Also disclosed are methods of making and using the same.

    Methods for full-length amplification of double-stranded linear nucleic acids of unknown sequences
    330.
    发明专利
    Methods for full-length amplification of double-stranded linear nucleic acids of unknown sequences 未知

    公开(公告)号：AU2014361815A1

    公开(公告)日：2016-05-26

    申请号：AU2014361815

    申请日：2014-12-14

    Applicant: ACADEMIA SINICA

    Inventor： CHIU KUO PING ,  NAI YU-SHIN

    IPC: C12Q1/68 ,  C12P19/34 ,  G01N33/48 ,  G01N33/50

    Abstract: An adaptor for use in amplifying all linear, double-stranded nucleic acid molecules of unknown sequences in a sample is disclosed. The adaptor consists of: (1) the first oligonucleotide (P- oligo) with a phosphate at the 5'end and without an additional thymine nucleotide at the 3' end; and (2) the second oligonucleotide (T~oligo) with an extra 3'-T and without a 5'-phosphate. The P-oligo and T-oligo are complementary to each other except at the 3' -T (thymine) in the T-oligo. The adaptor is ligated to nucleic acids of unknown sequences which have an extra A in the 3' end (3 ' ~A overhang) to form adaptor-ligated target nucleic acids. The T-oligo is then employed as a single primer for T-oligo-primed polymerase chain reaction (TOP-PCR) and amplifies the nucleic acids of unknown sequences in full-length.

Patent Agency Ranking